Satellite symposium: Leveraging Antibody Drug Conjugates in the care of Patients with Metastatic Urothelial Carcinoma; Potential for Immunotherapy Combination Treatment
A Talk by Prof. Yousef Zakharia , Dr Arnab Basu and Dr Shilpa Gupta
About this Talk
Learning Objectives
After completing the independent medical educational activity, learners will be able to:
- Describe clinical trials (both complete and ongoing) on the application of ADCs in the treatment of mUC patients.
- Explain the rationale of ADC use in mUC alone and in combination with immunotherapeutics.
- Recount emerging efficacy and safety data of ADCs in the treatment of mUC patients.
Expert Talk 1: Review of Sacituzumab Govitecan Data in Urothelial Cancer
Prof. Yousef Zakharia
*University of Iowa, Genitourinary Oncology Program, Iowa City, United States, USA
Expert Talk 2: Current evidence and future prospects of Enfortumab Vedotin in Urothelial Cancer
Dr Shilpa Gupta
*Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
Expert Talk 3: Emerging ADC Approaches in Urothelial Carcinoma
Dr Arnab Basu
O’Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL, United States.
Epert Panel Discussion and Questions & Answers
Panelists: Prof. Yousef Zakharia, Dr Shilpa Gupta and Dr Arnab Basu.
Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.
Conflict of interests: No known conflict of interests
Acknowledgment: This symposium is supported by educational grants from Astellas pharma.
